What is OBIO's current stock price?

OBIO (Orchestra BioMed Holdings, Inc.) is currently trading at $4.06 with a market cap of $243.1M.

What sector is Orchestra BioMed Holdings, Inc. in?

Orchestra BioMed Holdings, Inc. (OBIO) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is OBIO a good stock to buy?

Analysts have a Buy consensus on OBIO with a price target of $13.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

OBIO Orchestra BioMed Holdings, Inc.

Healthcare

$4.06-0.98%ClosedMarket Cap: $243.1M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

3.06

P/S

7.43

EV/EBITDA

-3.98

DCF Value

$-6.55

FCF Yield

-22.7%

Div Yield

0.0%

Margins & Returns

Gross Margin

99.3%

Operating Margin

-168.0%

Net Margin

-167.0%

ROE

-138.0%

ROA

-54.3%

ROIC

-62.6%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$110.0K	$-20.7M	$—
Q4 null	$30.9M	$6.2M	$—
FY null	$33.5M	$-52.7M	$—
Q3 null	$861.0K	$-20.8M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$13.00

Target (Median)

$13.00

Target Range

$13.00 - $13.00

2 Strong Buy5 Buy1 Hold0 Sell0 Strong Sell

B. Riley SecuritiesBuy

2026-05-19

HC Wainwright & Co.Buy

2026-05-14

BarclaysOverweight

2026-05-13

Chardan CapitalBuy

2026-03-12

BarclaysOverweight

2026-01-09

Trading Activity

Insider Trades

View All

Aryeh Jasondirector

BuyWed May 20

Hochman David Pdirector, officer: See Remarks

BuyTue May 19

Aryeh Jasondirector

BuyTue May 19

Fain Eric Sdirector

BuyMon May 18

RTW INVESTMENTS, LP10 percent owner

SellWed Apr 29

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.52

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

Peers

IVA